ValuEngine upgraded shares of Aradigm (NASDAQ:ARDM) from a sell rating to a hold rating in a research report released on Wednesday morning.

ARDM has been the topic of several other research reports. Zacks Investment Research cut shares of Aradigm from a buy rating to a hold rating in a research report on Wednesday, September 27th. Ladenburg Thalmann Financial Services reiterated a buy rating and set a $10.00 price target (up previously from $7.50) on shares of Aradigm in a research report on Monday, September 25th.

Shares of Aradigm (ARDM) traded down $1.16 during trading hours on Wednesday, hitting $2.26. 2,660,000 shares of the stock traded hands, compared to its average volume of 505,908. The company has a market capitalization of $34.23, a P/E ratio of -2.31 and a beta of 1.56. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of -1.59. Aradigm has a 52-week low of $0.78 and a 52-week high of $7.35.

Aradigm (NASDAQ:ARDM) last issued its quarterly earnings data on Thursday, November 2nd. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.05. The firm had revenue of $2.73 million for the quarter. equities research analysts expect that Aradigm will post -0.74 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Aradigm stock. Jane Street Group LLC purchased a new stake in shares of Aradigm Corporation (NASDAQ:ARDM) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 29,025 shares of the company’s stock, valued at approximately $122,000. Jane Street Group LLC owned 0.19% of Aradigm at the end of the most recent reporting period. Hedge funds and other institutional investors own 32.02% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at

Aradigm Company Profile

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm and related companies with's FREE daily email newsletter.